Your browser doesn't support javascript.
loading
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
Fouquet, G; Pegourie, B; Macro, M; Petillon, M O; Karlin, L; Caillot, D; Roussel, M; Arnulf, B; Mathiot, C; Marit, G; Kolb, B; Stoppa, A M; Brechiniac, S; Richez, V; Rodon, P; Banos, A; Wetterwald, M; Garderet, L; Royer, B; Hulin, C; Benbouker, L; Decaux, O; Escoffre-Barbe, M; Fermand, J P; Attal, M; Avet-Loiseau, H; Moreau, P; Facon, T; Leleu, X.
Afiliação
  • Fouquet G; Department of Blood Diseases, Hôpital Huriez, CHRU Lille, Lille.
  • Pegourie B; Department of Hematology, Hôpital A.Michallon, CHU Grenoble, Grenoble.
  • Macro M; Department of Hematology, Hôpital Côte de Nacre, CHU Caen, Caen.
  • Petillon MO; Department of Blood Diseases, Hôpital Huriez, CHRU Lille, Lille.
  • Karlin L; Department of Hematology, Centre Hospitalier Lyon-Sud, Lyon.
  • Caillot D; Department of Hematology, CHU de Dijon, Dijon.
  • Roussel M; Department of Hematology, CHU de Toulouse, Toulouse.
  • Arnulf B; Department of Hematology, Hôpital Saint Louis, APHP, Paris.
  • Mathiot C; Intergroupe Francophone du Myélome (IFM).
  • Marit G; Department of Hematology and Cell Therapy Service, CHU de Bordeaux, Pessac, France.
  • Kolb B; Department of Hematology, Hôpital Robert Debré, CHU Reims, Reims.
  • Stoppa AM; Department of Hematology, Institut Paoli Calmettes, Marseille.
  • Brechiniac S; Department of Hematology, CHU Avicennes, APHP, Paris.
  • Richez V; Department of Hematology, CHU Nice, Nice.
  • Rodon P; Department of Hematology, CH de Périgueux, Périgueux.
  • Banos A; Department of Hematology, CH de la Côte Basque, Bayonne.
  • Wetterwald M; Department of Hematology, CH de Dunkerque, Dunkerque.
  • Garderet L; Department of Hematology, CHU St-Antoine, Paris.
  • Royer B; Department of Hematology, Hôpital Sud, CHU Amiens, Amiens.
  • Hulin C; Department of Hematology, Hôpital de Nancy, Nancy.
  • Benbouker L; Department of Hematology, Hôpital de Tours, Tours.
  • Decaux O; Department of Hematology, CHU Rennes, Rennes.
  • Escoffre-Barbe M; Department of Hematology, CHU Rennes, Rennes.
  • Fermand JP; Department of Hematology, Hôpital Saint Louis, APHP, Paris.
  • Attal M; Department of Hematology, CHU de Toulouse, Toulouse.
  • Avet-Loiseau H; Department of Hematology, CHU de Toulouse, Toulouse.
  • Moreau P; Department of Hematology, CHU Nantes, Nantes.
  • Facon T; Department of Blood Diseases, Hôpital Huriez, CHRU Lille, Lille.
  • Leleu X; Department of Hematology, CHU Poitiers, Poitiers xavier.leleu@chu-poitiers.fr.
Ann Oncol ; 27(5): 902-7, 2016 05.
Article em En | MEDLINE | ID: mdl-26787238
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Talidomida / Resistencia a Medicamentos Antineoplásicos / Mieloma Múltiplo / Recidiva Local de Neoplasia Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Talidomida / Resistencia a Medicamentos Antineoplásicos / Mieloma Múltiplo / Recidiva Local de Neoplasia Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article